SciBase Releases Offer to Repurchase Outstanding Warrants
SciBase Holding AB (publ) is proud to announce the publication of an information document pertaining to its recent offer to repurchase all outstanding warrants of series TO 2. This significant offer aims to enhance shareholder value and facilitate a streamlined process for warrant holders.
Details of the Repurchase Offer
The TO 2 Offer was publicly announced, underlining a strategic move by SciBase to allow warrant holders to engage in this opportunity. The information document has received registration approval from the Swedish Financial Supervisory Authority. It provides vital details for stakeholders and can be accessed directly on SciBase's official website.
Availability of Information Document
For interested parties, the information document is readily available in both Swedish and English. In case of any discrepancies between the two versions, the Swedish version will take precedence. This ensures that all relevant details surrounding the TO 2 Offer are transparent and accessible.
Acceptance Period for the Offer
The acceptance period for the TO 2 Offer is set to commence, providing a structured timeline for warrant holders to respond. The acceptance will run from December 8 to January 8 of the upcoming year, after which SciBase will announce the outcomes.
Financial and Legal Advisors
In pursuit of this offer, SciBase has engaged sound financial and legal guidance. Bergs Securities and Birchtree Advisory have been appointed as financial advisors, whereas Advokatfirman Schjødt is serving as the legal advisor. Their expertise is instrumental in ensuring that this offer is executed efficiently and in compliance with applicable regulations.
Contact Points for Further Information
The company invites inquiries for additional information regarding the offer. Jesper Høiland, the Chairman of the Board, can be reached at +45 612 207 30, while Michael Colérus, the CFO, is available at +46 70 341 34 72. This open line of communication demonstrates SciBase's commitment to its stakeholders.
About SciBase
SciBase is a leading global medical technology company dedicated to improving health outcomes in dermatology settings through innovation. The company is recognized for developing Nevisense, a cutting-edge platform that integrates AI with advanced electrical impedance spectroscopy (EIS) technology. This unique combination not only elevates diagnostic accuracy but also empowers healthcare providers to manage skin health proactively.
The organization was founded on over 20 years of research from the Karolinska Institute, reflecting a robust foundation in dermatology that continues to drive its mission. SciBase’s commitment is directed toward reducing patient suffering, enhancing clinician efficacy, and ultimately decreasing healthcare costs.
Recent Market Presence
Since its admission to the Nasdaq First North Growth Market exchange in 2015, SciBase has continually focused on innovation and market growth. Today, it remains at the forefront of dermatological advancements. The company's Certified Adviser is Carnegie Investment Bank AB (publ), ensuring strict adherence to market regulations while maximizing shareholder engagement.
Frequently Asked Questions
What is the purpose of the TO 2 Offer?
The TO 2 Offer aims to repurchase outstanding warrants, boosting shareholder value and providing a streamlined process for warrant holders.
Where can I access the information document?
The information document is available on the SciBase official website for stakeholders to review its details.
When does the acceptance period for the offer begin?
The acceptance period runs from December 8 to January 8, allowing warrant holders the opportunity to participate.
Who can I contact for further information about the offer?
You can contact Jesper Høiland or Michael Colérus for any inquiries regarding the offer or additional details.
What technology does SciBase use in its solutions?
SciBase utilizes a unique platform that combines artificial intelligence with electrical impedance spectroscopy for enhanced dermatological diagnostics.
